Effectiveness of Clopidogrel Resinate(PRegrel) in Patients Undergoing Percutaneous Coronary Intervention Compared With ClopiDogrEl Bisulfate(Plavix).

Trial Profile

Effectiveness of Clopidogrel Resinate(PRegrel) in Patients Undergoing Percutaneous Coronary Intervention Compared With ClopiDogrEl Bisulfate(Plavix).

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Coronary artery disease; Embolism and thrombosis
  • Focus Therapeutic Use
  • Acronyms PRIDE
  • Most Recent Events

    • 15 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.
    • 15 Jun 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top